<DOC>
	<DOCNO>NCT00004582</DOCNO>
	<brief_summary>The purpose study see ABT-378/ritonavir plus efavirenz safe effective lowering amount HIV blood patient treat 1 protease inhibitor ( PI ) .</brief_summary>
	<brief_title>ABT-378/Ritonavir Efavirenz HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor Past</brief_title>
	<detailed_description>All patient take ABT-378/ritonavir efavirenz ; placebo study . Patients take study medication 48 week , time 15 study visit . There possibility study extension 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load ( level HIV blood ) least 1,000 copies/ml . Have receive stable ( change ) antiHIV treatment include least 1 PI least 8 week prior study entry . Have receive 1 PI least 12 week time past . Exclusion Criteria Patients eligible study : Have active opportunistic ( AIDSrelated ) infection within past 30 day . Have ever receive nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) , delavirdine , nevirapine , efavirenz . Have receive certain medication . Are pregnant breastfeeding . Abuse alcohol drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>ABT 378</keyword>
	<keyword>efavirenz</keyword>
</DOC>